Open AccessConcern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination
Author(s) -
M A Haimei
Publication year - 2021
Publication title -
clinical and applied thrombosis/hemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.643
H-Index - 53
eISSN - 1938-2723
pISSN - 1076-0296
DOI - 10.1177/10760296211040110
Subject(s) - covid-19 , adverse effect , medicine , vaccination , virology , outbreak , thrombosis , clinical trial , immunology , intensive care medicine , infectious disease (medical specialty) , disease
Since the outbreak of Covid-19 in December, 2019, scientists worldwide have been committed to developing COVID-19 vaccines. Only when most people have immunity to SARS-CoV-2, COVID-19 can reduce even wholly overcome. So far, nine kinds of COVID-19 vaccines have passed the phase III clinical trials and have approved for use. At the same time, adverse reactions after COVID-19 vaccination have also reported. This paper focuses on the adverse effects of thrombosis and thrombocytopenia caused by the COVID-19 vaccine, especially the adenovirus-vector vaccine from AstraZeneca and Pfizer, and discusses its mechanism and possible countermeasures.